IL309395A - Sequential innate and adaptive immune modulation for cancer treatment - Google Patents

Sequential innate and adaptive immune modulation for cancer treatment

Info

Publication number
IL309395A
IL309395A IL309395A IL30939523A IL309395A IL 309395 A IL309395 A IL 309395A IL 309395 A IL309395 A IL 309395A IL 30939523 A IL30939523 A IL 30939523A IL 309395 A IL309395 A IL 309395A
Authority
IL
Israel
Prior art keywords
innate
sequential
cancer treatment
adaptive immune
immune modulation
Prior art date
Application number
IL309395A
Other languages
Hebrew (he)
Inventor
Wittig Burghardt
J?Hnig Peter
L?Hr Janine
Original Assignee
Wittig Burghardt
J?Hnig Peter
L?Hr Janine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wittig Burghardt, J?Hnig Peter, L?Hr Janine filed Critical Wittig Burghardt
Publication of IL309395A publication Critical patent/IL309395A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/282Platinum compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL309395A 2021-06-16 2022-06-16 Sequential innate and adaptive immune modulation for cancer treatment IL309395A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21179848.3A EP4104830A1 (en) 2021-06-16 2021-06-16 Sequential innate and adaptive immune modulation for cancer treatment
PCT/EP2022/066533 WO2022263618A1 (en) 2021-06-16 2022-06-16 Sequential innate and adaptive immune modulation for cancer treatment

Publications (1)

Publication Number Publication Date
IL309395A true IL309395A (en) 2024-02-01

Family

ID=76942706

Family Applications (1)

Application Number Title Priority Date Filing Date
IL309395A IL309395A (en) 2021-06-16 2022-06-16 Sequential innate and adaptive immune modulation for cancer treatment

Country Status (7)

Country Link
EP (2) EP4104830A1 (en)
JP (1) JP2024521514A (en)
CN (1) CN117794549A (en)
AU (1) AU2022292917A1 (en)
CA (1) CA3222919A1 (en)
IL (1) IL309395A (en)
WO (1) WO2022263618A1 (en)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4843820A (en) 1988-04-29 1989-07-04 Allied-Signal Inc. Brake system in-line fast fill valve
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DE19935756A1 (en) 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Covalently closed nucleic acid molecule for immune stimulation
US20060241076A1 (en) 2005-04-26 2006-10-26 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
BRPI0618473A2 (en) * 2005-11-11 2011-08-30 Pfizer combinations and methods of using an immunomodulatory oligodeoxynucleotide
US7662949B2 (en) 2005-11-25 2010-02-16 Coley Pharmaceutical Gmbh Immunostimulatory oligoribonucleotides
KR20090058584A (en) 2006-10-26 2009-06-09 콜리 파마슈티칼 게엠베하 Oligoribonucleotides and uses thereof
ES2750608T3 (en) 2013-07-25 2020-03-26 Exicure Inc Nucleic acid-based spherical constructs as immunostimulatory agents for prophylactic and therapeutic use
EP3392345A1 (en) * 2017-04-22 2018-10-24 Mologen AG Biomarker for small cell lung cancer therapy
EP3691749A1 (en) * 2017-08-31 2020-08-12 Mologen AG Tlr-9 agonists for modulation of tumor microenvironment

Also Published As

Publication number Publication date
CN117794549A (en) 2024-03-29
JP2024521514A (en) 2024-05-31
EP4355337A1 (en) 2024-04-24
CA3222919A1 (en) 2022-12-22
EP4104830A1 (en) 2022-12-21
AU2022292917A1 (en) 2024-01-04
WO2022263618A1 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
IL261008B1 (en) Combination immune therapy and cytokine control therapy for cancer treatment
IL297418B1 (en) Combination immune therapy and cytokine control therapy for cancer treatment
IL272740A (en) Combination immune therapy and cytokine control therapy for cancer treatment
EP3876965A4 (en) Combination therapies of microorganisms and immune modulators for use in treating cancer
IL275940A (en) Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
IL281441A (en) Anti-cxcl13 antibodies for treating autoimmune diseases and cancer
FI3773689T3 (en) Antigenic peptides for prevention and treatment of cancer
IL263394A (en) Methods of activating dysfunctional immune cells and treatment of cancer
EP3752528A4 (en) Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint
SG11202005296SA (en) Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
IL309395A (en) Sequential innate and adaptive immune modulation for cancer treatment
GB201810635D0 (en) Peptides and cancer treatment
IL286326A (en) Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer
EP4084822A4 (en) Individualized vaccines for cancer treatment and prevention
IL288591A (en) Methods and uses for treating cancer
IL287923A (en) Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating luts
SG11202103148QA (en) Methods of treating residual breast cancer with trastuzumab emtansine
GB201815694D0 (en) Prevention and treatment of cancer
GB201809946D0 (en) Prevention and treatment of cancer
SG11202108140SA (en) Anti-bag2 antibody and methods of treating cancer
GB202303784D0 (en) Cancer treatment
GB202217305D0 (en) Cancer treatment
GB202211123D0 (en) Cancer treatment
GB202210038D0 (en) Cancer treatment
GB202206948D0 (en) Cancer treatment